Provectus Biopharmaceuticals, INC Form 4 insider transactions

Provectus Biopharmaceuticals CEO Edward Pershing acquired an $65,000 convertible promissory note, convertible into Series D-1 Preferred Stock.

Provectus Biopharmaceuticals' CEO, Edward Pershing, acquired an 8% unsecured convertible promissory note valued at $20,000, convertible into Series D-1 Preferred Stock.

PROVECTUS BIOPHARMACEUTICALS CEO Edward Pershing converted an 8% unsecured convertible promissory note into Series D-1 Convertible Preferred Stock.

PROVECTUS BIOPHARMACEUTICALS CEO Edward Pershing acquired an 8% unsecured convertible promissory note valued at $60,000, convertible into Series D-1 Preferred Stock.

Provectus Biopharmaceuticals CEO Edward Pershing acquired an 8% unsecured convertible promissory note valued at $35,000.

Provectus Biopharmaceuticals CEO Edward Pershing converted an 8% unsecured convertible promissory note into Series D-1 Preferred Stock, increasing his equity stake.

Provectus Biopharmaceuticals CEO Edward Pershing converted an 8% unsecured convertible promissory note into Series D-1 Convertible Preferred Stock.

PROVECTUS BIOPHARMACEUTICALS CEO Edward Pershing acquired an 8% unsecured convertible promissory note valued at $35,000, convertible into Series D-1 Preferred Stock.

Provectus Biopharmaceuticals CEO Edward Pershing acquired an 8% unsecured convertible promissory note valued at $35,000, convertible into Series D-1 Preferred Stock.

Provectus Biopharmaceuticals CEO Edward Pershing acquired a $30,000 convertible note while simultaneously disposing of $1.25 million in Series D-1 Preferred Stock.

Provectus Biopharmaceuticals CEO Edward Pershing converted an 8% unsecured convertible promissory note into Series D-1 Convertible Preferred Stock.

PROVECTUS BIOPHARMACEUTICALS CEO Edward Pershing acquired an 8% unsecured convertible promissory note as part of the company's 2025 financing.

Provectus Biopharmaceuticals CEO Edward Pershing converted an 8% unsecured convertible promissory note into Series D-1 Convertible Preferred Stock.

Provectus Biopharmaceuticals CEO Edward Pershing converted an $50,000 unsecured promissory note into 18,880 shares of Series D-1 Convertible Preferred Stock.

Edward Pershing, CEO of Provectus Biopharmaceuticals, converted an 8% unsecured convertible promissory note into Series D-1 Preferred Stock, which then converted into common stock, increasing his direct beneficial ownership.

Edward Pershing, CEO and Director of Provectus Biopharmaceuticals, Inc., converted an 8% unsecured convertible promissory note into Series D-1 Convertible Preferred Stock, further detailing his beneficial ownership and future equity structure.

Edward Pershing, CEO and Director of Provectus Biopharmaceuticals, Inc., has converted an 8% unsecured convertible promissory note into Series D-1 Convertible Preferred Stock, as disclosed in a recent SEC Form 4 filing.

Provectus Biopharmaceuticals CEO Edward Pershing acquired an 8% unsecured convertible promissory note valued at $25,000, convertible into Series D-1 Preferred Stock, as part of the company's 2025 financing.

Edward Pershing, CEO and Director of Provectus Biopharmaceuticals, Inc., has acquired an $85,000 convertible promissory note as part of the company's 2025 financing efforts.

CEO Edward Pershing reports acquisition of convertible promissory note and preferred stock in Provectus Biopharmaceuticals.

CEO Edward Pershing reports acquisition of an unsecured convertible promissory note and Series D-1 Convertible Preferred Stock in Provectus Biopharmaceuticals' 2025 Financing.

CEO Edward Pershing converted an 8% unsecured convertible promissory note into Series D-1 Convertible Preferred Stock on April 29, 2025.

CEO Edward Pershing reports acquisition of convertible securities in Provectus Biopharmaceuticals' 2025 financing.

CEO Edward Pershing reports the conversion of a convertible promissory note into Series D-1 Convertible Preferred Stock.

CEO Edward Pershing reports the conversion of a convertible note into Series D-1 Preferred Stock of Provectus Biopharmaceuticals.

CEO Edward Pershing reports acquisition of convertible promissory note and convertible preferred stock in Provectus Biopharmaceuticals.

CEO Edward Pershing converted an 8% unsecured convertible promissory note into Series D-1 Convertible Preferred Stock on March 26, 2025.

CEO Edward Pershing converted an 8% unsecured convertible promissory note into Series D-1 Convertible Preferred Stock on March 21, 2025.

CEO Edward Pershing reports acquisition of convertible promissory note and preferred stock in Provectus Biopharmaceuticals.

CEO Edward Pershing converted an 8% unsecured convertible promissory note into Series D-1 Convertible Preferred Stock on February 27, 2025.